| Old Articles: <Older 4911-4920 Newer> |
|---|
 |
The Motley Fool
June 13, 2008
Brian Lawler |
Lilly Patches Its Pipeline An early-stage compound joins the pharmaceutical's upcoming roster.   |
The Motley Fool
June 13, 2008
Brian Orelli |
Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers. |
The Motley Fool
June 13, 2008
Brian Orelli |
High-Tech Health-Care Stocks to Keep Dad Healthy These stocks will help dad grow older, stay healthy, and make money. |
The Motley Fool
June 12, 2008
Brian Orelli |
Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab. |
The Motley Fool
June 12, 2008
Brian Lawler |
Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright. |
Chemistry World
June 11, 2008
James Mitchell Crow |
GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations. |
The Motley Fool
June 11, 2008
Brian Lawler |
Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over. |
The Motley Fool
June 11, 2008
Brian Orelli |
Dueling Fools: Pfizer Bull The bullish opinion on Pfizer is that this may be the best time to buy this stock. |
The Motley Fool
June 11, 2008
Brian Orelli |
Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
| <Older 4911-4920 Newer> Return to current articles. |
